Cloud-Clone highlights active ACE2 protein for cardiorenal and fibrosis research
Cloud-Clone is promoting a recombinant active ACE2 protein for studies in cardiovascular disease, kidney injury, fibrosis, virology and peptide drug development. The company says the reagent is functionally validated to support binding, enzymatic and cell-based workflows that depend on properly folded ACE2.
Why it matters: - ACE2 sits at the center of both cardiovascular biology and coronavirus entry, so a well-characterized recombinant version can serve multiple research fields at once. - Active ACE2 reagents are used in studies of cardiorenal disease, organ fibrosis, viral-host interaction and pre-clinical drug discovery. - Reliable enzymatic activity and receptor-binding performance matter because poor folding or weak activity can distort binding assays, cell studies and screening results.
What happened: - Cloud-Clone is offering a recombinant active ACE2 protein for in-vitro research programs. - The product is positioned for mechanistic studies across cardiovascular science, virology, nephrology, pulmonary injury and peptide therapeutic development. - The company says the reagent is functionally validated and designed to preserve ACE2 catalytic and binding function.
The details: - ACE2 is a type-I transmembrane glycoprotein and zinc-dependent metallopeptidase. - ACE2 converts angiotensin II into angiotensin 1-7, which is linked to vasodilation, anti-inflammatory and anti-fibrotic effects. - ACE2 and ACE jointly help regulate blood pressure and organ homeostasis. - The extracellular domain of ACE2 contains a conserved HEXXH zinc-binding motif that is essential for activity. - ACE inhibitors such as captopril and lisinopril do not suppress ACE2 catalytic function. - ACE2 is expressed in alveolar epithelial cells, cardiomyocytes, renal tubular epithelial cells, intestinal epithelial cells and vascular endothelial cells. - Membrane-bound ACE2 can be cleaved into soluble sACE2, which participates in systemic signal regulation. - ACE2 also hydrolyzes other peptide substrates, including apelin and neurotensin. - Multiple coronaviruses use ACE2 as a host-cell attachment site, and spike-protein receptor-binding domains engage ACE2 to facilitate entry. - Virus binding and internalization can reduce surface ACE2, increase angiotensin II accumulation and amplify inflammatory signaling. - Cloud-Clone says the protein was produced with optimized eukaryotic expression and purification workflows to preserve biological function. - The product is supplied as sterile vacuum-lyophilized material. - Short-term ambient-temperature transport does not compromise functional performance, and repeated freeze-thaw cycles should be limited to fewer than three times. - The protein re-dissolves readily without visible precipitation. - Application-oriented technical support is available from Cloud-Clone.
Between the lines: - The pitch is aimed at researchers who need one reagent for both ACE2’s physiologic role and its role as a viral receptor. - Cloud-Clone is emphasizing function over simple purity or concentration, which is a common pain point in recombinant protein workflows. - The company is also framing ACE2 as a platform reagent for screening, not just a single-use assay component.
What’s next: - Researchers can use the protein in enzyme-activity assays, binding assays, pseudovirus neutralization workflows, cell-function studies and high-throughput screening. - The reagent is intended to support studies of hypertension, cardiac hypertrophy, diabetic nephropathy, renal fibrosis, acute kidney injury, ARDS and fibrotic signaling. - Cloud-Clone says the protein can also support antibody development, immuno-assay development and structural biology work such as crystallography and cryo-electron microscopy.
The bottom line: - Cloud-Clone is packaging active ACE2 as a multi-purpose research tool for labs working across cardiovascular disease, fibrosis, pulmonary injury and virus-host interaction.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Journal of Professional Transportation
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.